Company news

Cascade Copper Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Oncothyreon announces clinical data from three product candidates presented at American Society of Clinical Oncology (ASCO) Annual Meeting

May 30, 2009

Oncothyreon announces closing of $11.1 million registered direct financing

May 27, 2009

Oncothyreon announces commitments to purchase $11.1 million of company securities in a registered direct financing

May 20, 2009

Oncothyreon's PX-866 is effective in preclinical model of pulmonary fibrosis

May 18, 2009

Oncothyreon announces presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

May 18, 2009

Oncothyreon reports first quarter 2009 financial results

May 14, 2009

Oncothyreon regains compliance with NASDAQ listing requirements

March 16, 2009

Oncothyreon to present at Invest Northwest 2009

March 13, 2009

Oncothyreon reports full year and fourth quarter 2008 financial results

March 9, 2009

Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call

March 3, 2009

Oncothyreon to present at BIO CEO & Investor Conference 2009

February 3, 2009

Oncothyreon announces development plans and personnel changes and updates financial guidance

December 18, 2008

Merck KGaA acquires manufacturing rights for Stimuvax from Oncothyreon

December 18, 2008

Oncothyreon reports third quarter 2008 financial results

November 6, 2008

Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference

November 4, 2008

Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call

November 3, 2008

Oncothyreon to present at BIO Investor Forum 2008

October 24, 2008

Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards

September 17, 2008

Oncothyreon announces prioritization plan for development programs

September 2, 2008

Oncothyreon announces public common stock offering

September 2, 2008

Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market

August 20, 2008

Oncothyreon reports second quarter 2008 financial results

August 7, 2008

Oncothyreon initiates Phase 1 trial of PX-866 cancer compound

June 17, 2008

Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer

June 11, 2008

Oncothyreon announces appointments to board of directors

June 9, 2008

Stimuvax Phase 1/2 survival data support prior results

June 2, 2008

Oncothyreon to receive milestone payment

May 14, 2008

Oncothyreon Reports First Quarter 2008 Financial Results

May 7, 2008

Oncothyreon files investigational new drug application for PX-866 oncology compound

May 1, 2008

Data for Oncothyreon's PX-12 and PX-866 presented at AACR Annual Meeting

April 16, 2008

Oncothyreon's PX-478 enhances antitumor effects of radiation therapy in preclinical models of pancreatic and brain cancer

April 15, 2008

Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting

April 10, 2008

Oncothyreon announces effectiveness of shelf registration statement

April 9, 2008

Oncothyreon announces issuance of patent for PX-867

March 20, 2008

Oncothyreon to present at upcoming investment conferences

March 12, 2008

Oncothyreon reports full year and fourth quarter 2007 financial results

March 10, 2008

Oncothyreon announces March 10th webcast of fourth quarter and full year financial results conference call

March 7, 2008

Oncothyreon's PX-478 is effective in preclinical model of human lung cancer

February 25, 2008

Oncothyreon launches new corporate website

February 5, 2008

Oncothyreon to present at BIO CEO & Investor Conference

February 4, 2008

Oncothyreon highlights corporate and clinical objectives for 2008

January 28, 2008

Oncothyreon regains compliance with NASDAQ minimum bid listing requirement

January 2, 2008

Oncothyreon to receive $5 million payment

December 17, 2007

Oncothyreon to begin trading today on NASDAQ and TSX

December 11, 2007

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.